Paladin Labs Announces the Canadian Launch of Emtrix®įor complete list of press releases click Here. Paladin Labs Announces the Canadian Launch of Zincofax® Spray Announces the Launch of Unisom® Snore Relief, the Only Natural Health Product Throat Spray Available in Canada to Help Relieve Symptoms Associated with SnoringĪRIAD and Paladin Announce Commercial Distribution Agreement for Iclusig (Ponatinib) in Canada Announces Launch of New Indication for XIAFLEX® (Collagenase Clostridium Histolyticum), Broadening Its Use to the Treatment of Appropriate Patients with Peyronie's Disease Announces Approval of Envarsus PA TM (tacrolimus prolonged-release tablets) in Canadaīioprojet and Endo Jointly Announce Agreement for Paladin Labs Inc. Helsinn and Endo Announce Agreement for Paladin Labs Inc. Movapo® (apomorphine hydrochloride) for Patients with Advanced Parkinson's Disease Now Reimbursed in Most Canadian Provinces to Commercialize Abaloparatide in CanadaĮnvarsus® PA Once-daily Immunosuppressive Therapy for Kidney and Liver Transplant Patients is Now Reimbursed in Ontario, Quebec, Manitoba and Saskatchewan Announces Approval of Wakix® (pitolisant) in CanadaĪDVANZ PHARMA and Endo Announce Partnership for Paladin Labs to Commercialize Xydalba® (dalbavancin hydrochloride) in CanadaĮndo Announces Licensing Agreement for Paladin Labs Inc. Announces the Launch of Xydalba® (dalbavancin for injection) in Canada Adrian graduated from the Royal Institute of Chemistry at Salford University.Paladin Labs Announces Health Canada’s Filing Acceptance of Cenobamate Tablets as an Adjunctive Therapy for the Management of Partial-Onset Seizures in Adults with Epilepsy He also serves as the Chairman of the Board of Directors at AcelRx Pharmaceuticals, Inc., and Chairman of the Board at Akebia Therapeutics, Inc. from 2002 until the acquisition of the company by Abbott Laboratories in 2016 for $3.7 billion.Īdrian has also held general management and senior international and national marketing positions at Novartis, SmithKline Beecham and ICI (now part of AstraZeneca).
Prior to joining Sepracor, Adrian was President and CEO of Kos Pharmaceuticals, Inc. Prior to Inspire, Adrian served as President and CEO of Sepracor, Inc., where under his leadership, Sepracor conducted multiple strategic corporate development activities prior to its acquisition by Dainippon Sumitomo Pharma Co for $2.6 billion. Prior to joining Auxilium, from September 2011 until November 2011, Adrian served as Chairman and CEO of Neurologix and President and CEO of Inspire Pharmaceuticals, Inc., where he led the company through a strategic acquisition by global pharmaceutical leader Merck & Co., Inc., for $430 million. from December 2011 until its acquisition by Endo International plc in January 2015 for $2.6 billion. Founder of Bradley Construction Management LLC, Mark Bradley currently is Chief Financial Officer & Executive Vice President at Endo International Plc and. Prior to joining Aralez, Adrian served as CEO and President of Auxilium Pharmaceuticals, Inc. He served in this role with the company’s predecessor, POZEN Inc.
Prior to this role, Adrian held the position of CEO of Aralez Pharmaceuticals Inc., a pharmaceutical company that focuses on the development, acquisition and commercialization of cardiovascular, pain and other therapies, and was a member of the Aralez Board of Directors from February 2016 to January 2019. Adrian has served as Chairman of Impel’s Board of Directors since January 2020 and as Chief Executive Officer (CEO) since May 2020.
0 kommentar(er)
